Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

AmpliPhi Biosciences Corporation (AKA: Targeted Genetics Corporation~RGene Therapeutics Inc)
Profile last edited on: 12/2/2023      CAGE: -----      UEI: ----------

Business Identifier: Gene therapy products to prevent and to treat acquired and inherited diseases
Year Founded
1989
First Award
1995
Latest Award
1997
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1100 Olive Way Suite 100
Seattle, WA 98101
   (206) 623-7612
   targen@targen.com
   www.targen.com
Location: Single
Congr. District: 07
County: King

Public Profile

Currently there is no description available for this company.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
1
Conversion Rate
33.33%
Phase I Dollars
$297,895
Phase II Dollars
$699,998
Total Awarded
$997,893

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NYSE : APHB
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
1997 2 NIH $799,623
Project Title: Development of an AAV CFTR Vector Production System
1996 1 NIH $100,000
Project Title: Integrase Mediated Gene Delivery
1996 1 NIH $98,270
Project Title: ELA Gene Therapy In Ovarian And Breast Cancer BB IND 6178

Key People / Management

  Susan Robinson -- President

  Barrie J Carter -- Executive VP & CSO

  Robert L De Jager

  H Stewart Parker -- Former President and Chief Executive Officer

  Anna M Skalka

Company News

Jan 04 2019
AmpliPhi Biosciences and C3J Therapeutics Agree to Merge: Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics